Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CAN508 是一种有效的 ATP 竞争性 CDK9/cyclin T1 抑制剂,IC50 为 0.35 μM。它还是 Cdk2-cyclin E 对 ATP 的竞争性抑制剂,Ki 和 IC50 值分别为 13.3 和 20 µM。它对 CDK9/cyclin T 的选择性是其他 CDK/cyclin 复合物的 38 倍,有抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 279 | 现货 | ||
5 mg | ¥ 556 | 现货 | ||
10 mg | ¥ 898 | 现货 | ||
25 mg | ¥ 1,630 | 现货 | ||
50 mg | ¥ 2,420 | 现货 | ||
100 mg | ¥ 3,580 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 625 | 现货 |
产品描述 | CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. It is also a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 μM, respectively.CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity. |
靶点活性 | CDK9-CyclinT1:0.35 μM |
体外活性 | The most potent inhibitor,CAN508, reduced the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays.?Further observed cellular effects included decreased phosphorylation of the retinoblastoma protein and the C-terminal domain of RNA polymerase II, inhibition of mRNA synthesis, and induction of the tumor suppressor protein p53, all of which are consistent with inhibition of CDK9. |
分子量 | 218.22 |
分子式 | C9H10N6O |
CAS No. | 140651-18-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (1145.63 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.5825 mL | 22.9127 mL | 45.8253 mL | 114.5633 mL |
5 mM | 0.9165 mL | 4.5825 mL | 9.1651 mL | 22.9127 mL | |
10 mM | 0.4583 mL | 2.2913 mL | 4.5825 mL | 11.4563 mL | |
20 mM | 0.2291 mL | 1.1456 mL | 2.2913 mL | 5.7282 mL | |
50 mM | 0.0917 mL | 0.4583 mL | 0.9165 mL | 2.2913 mL | |
100 mM | 0.0458 mL | 0.2291 mL | 0.4583 mL | 1.1456 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CAN508 140651-18-9 Cell Cycle/Checkpoint CDK inhibit CAN-508 ATP-competitive Cyclin dependent kinase esophageal cells Inhibitor adenocarcinoma HT-29 CAN 508 inhibitor